New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s […]
Dexcom
Dexcom quadruples number of shares
Dexcom (Nasdaq:DXCM) recently filed a restated certificate of incorporation to effect a four-for-one forward stock split. Shares of DXCM were down 0.9% at $293.85 per share at market close on Friday, June 10. Following the stock split, shares moved down 75.33% to $72.50 before the market opened this morning. At market open, shares were down 3.4% […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. The […]
Dexcom CEO expects ‘science boom’ with CGM, automated insulin delivery
With the G7 nearing FDA clearance, Dexcom leadership foresees major innovations for integrated automated insulin delivery down the line. Kevin Sayer began thinking about automated insulin delivery all the way back in 1994 when he was working at MiniMed. Nearly 30 years later, as CEO of Dexcom (Nasdaq:DXCM), that space continues to pique his interest. In the […]
Dexcom quashes talk of Insulet merger, says discussions are not ongoing
Dexcom (Nasdaq:DXCM) today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD). Last week, reports circulated saying talks over a potential acquisition were ongoing, with an agreement between the two diabetes technology developers on the horizon in the coming weeks. On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 […]
Report: Dexcom in talks to acquire Insulet
Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous […]
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented […]
CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
Dexcom study shows strong accuracy for next-gen G7 CGM in pediatric T1D patients
Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children. San Diego-based Dexcom’s study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review. Get the full […]
Dexcom dips after hours on Q1 EPS miss, remains confident of U.S. G7 launch this year
Dexcom (Nasdaq:DXCM) shares took a hit after hours today on first-quarter results that fell short of the consensus earnings forecast. DXCM shares were down 6.2% at $387.61 per share after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.3%. Get the full story […]
Welldoc says CGM, digital health platform combination provides better glycemic outcomes
Welldoc said that its combination of real-time continuous glucose monitoring (CGM) and digital health impacts glucose control in type 2 diabetes. Columbia, Maryland-based Welldoc presented data at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from a study of real-time CGM and digital health in individuals with type 2 diabetes not treated with insulin. […]
